Understanding the Connection Between FDA Regulation and Reimbursement for Clinical Lab Testing

Clinical laboratories are navigating a changing landscape where regulatory decisions increasingly influence reimbursement outcomes. While some laboratory developed tests can reach the market without FDA review, evolving policies and coverage frameworks are raising important questions about how regulatory strategy may affect payer acceptance, coding pathways, and long-term financial performance. In this educational webinar, regulatory attorney Christine Bump of Penn Avenue Law and Ann Lambrix, Executive Director of RCM Consulting at Lighthouse Lab Services, examine the growing relationship between regulatory positioning and reimbursement strategy. Attendees will gain insight into how intended use language, clinical utility evidence, FDA pathways, and payer expectations can shape coverage decisions and reimbursement opportunities. The discussion will also explore emerging developments affecting laboratory reimbursement, including changes within MolDx and what they may signal for the future of molecular diagnostics coverage and policy direction. Jump to: 0:00 Welcome & Introductions 4:30 Why FDA Regulation Still Matters After the LDT Court Decision 8:15 The Enhancing CLIA Act Explained 14:45 Could VALID Act Return? 17:45 Why Some Laboratories Still Pursue FDA Clearance 24:20 FDA Approval Does NOT Guarantee Reimbursement 30:30 FDA vs. Medical Necessity: Two Different Standards 35:00 FDA/CMS Parallel Review Program 41:20 RAPID Program Overview 49:30 New Medicare Coverage Pathway for Multi-Cancer Early Detection (MCED) Tests 59:15 Emerging Reimbursement Trends Affecting Laboratories This session is designed for: -Lab Owners and Stakeholders -Regulatory Consultants -Revenue Cycle and Billing Leaders -Pathologists -Lab Compliance Advisors -Bench-Level Scientists seeking to gain a broader understanding of ongoing regulations